Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876978 | 0.88 | LGMN (0.38) | KDM4EALDH1A1LMNA | |
| SCHEMBL9749472 | 0.83 | MAPT (0.35) | ALDH1A1LMNA | |
| SCHEMBL26317301 | 0.76 | CYP11B1 (0.33) | — | |
| SCHEMBL612703 | 0.74 | LGMN (0.37) | KDM4EALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL430973 | 0.72 | MAPT (0.42) | ALDH1A1LMNA | |
| SCHEMBL9894976 | 0.70 | KDM4E (0.35) | KDM4EALDH1A1LMNA | |
| SCHEMBL13004982 | 0.70 | MAPT (0.34) | LMNATSHR | |
| SCHEMBL23484653 | 0.69 | USP2 (0.38) | KDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL14779490 | 0.67 | POLB (0.31) | — | |
| SCHEMBL12705404 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2630144-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2012054367-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054367-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
| US-5545703-A | Electroconductive polymers from unsaturated polymerizable TTF, TCNQ and DCQDI monomers | NORTHROP GRUMMAN CORPORATION (US) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | KDM4E 937/4885ALDH1A1 1866/4885LMNA 4810/4885 |
| US-20120270868-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | KDM4E 1910/4885ALDH1A1 3138/4885LMNA 1918/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | KDM4E 923/4885ALDH1A1 316/4885LMNA 4480/4885 |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | KDM4E 1787/4885ALDH1A1 3398/4885LMNA 3086/4885 |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | KDM4E 937/4885ALDH1A1 1866/4885LMNA 4810/4885 |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | KDM4E 937/4885ALDH1A1 1866/4885LMNA 4810/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | KDM4E 923/4885ALDH1A1 316/4885LMNA 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.